431 related articles for article (PubMed ID: 19243922)
1. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
[TBL] [Abstract][Full Text] [Related]
2. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
3. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Schafer J; Hovde LB; Simonson D; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
[TBL] [Abstract][Full Text] [Related]
4. In vitro selection of fluoroquinolone resistance in Brucella melitensis.
Ravanel N; Gestin B; Maurin M
Int J Antimicrob Agents; 2009 Jul; 34(1):76-81. PubMed ID: 19261448
[TBL] [Abstract][Full Text] [Related]
5. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
Turner AK; Nair S; Wain J
J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
[TBL] [Abstract][Full Text] [Related]
6. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
[TBL] [Abstract][Full Text] [Related]
7. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients.
Kim JM; Kim JS; Kim N; Jung HC; Song IS
J Antimicrob Chemother; 2005 Nov; 56(5):965-7. PubMed ID: 16159928
[TBL] [Abstract][Full Text] [Related]
8. In vitro-selected resistance to fluoroquinolones in two Brucella strains associated with mutational changes in gyrA.
Turkmani A; Psaroulaki A; Christidou A; Chochlakis D; Tabaa D; Tselentis Y
Int J Antimicrob Agents; 2008 Sep; 32(3):227-32. PubMed ID: 18583100
[TBL] [Abstract][Full Text] [Related]
9. In vitro development of resistance to DX-619 and other quinolones in enterococci.
Wickman PA; Black JA; Smith Moland E; Thomson KS; Hanson ND
J Antimicrob Chemother; 2006 Dec; 58(6):1268-73. PubMed ID: 17062613
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Deryke CA; Du X; Nicolau DP
J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
[TBL] [Abstract][Full Text] [Related]
11. Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila.
Almahmoud I; Kay E; Schneider D; Maurin M
J Antimicrob Chemother; 2009 Aug; 64(2):284-93. PubMed ID: 19474069
[TBL] [Abstract][Full Text] [Related]
12. Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposure.
Hovde LB; Simonson DA; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Mar; 60(3):295-9. PubMed ID: 18053674
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
Lister PD
Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
[TBL] [Abstract][Full Text] [Related]
14. In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations.
De Vecchi E; Nicola L; Ossola F; Drago L
J Antimicrob Chemother; 2009 Apr; 63(4):721-7. PubMed ID: 19218275
[TBL] [Abstract][Full Text] [Related]
15. [Fluoroquinolone resistance mutations in topoisomerase genes of Salmonella typhimurium isolates].
Guo Y; Pei X; Liu X
Wei Sheng Yan Jiu; 2004 Sep; 33(5):591-4. PubMed ID: 15612489
[TBL] [Abstract][Full Text] [Related]
16. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
[TBL] [Abstract][Full Text] [Related]
17. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
[TBL] [Abstract][Full Text] [Related]
18. Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin.
Li X; Mariano N; Rahal JJ; Urban CM; Drlica K
Antimicrob Agents Chemother; 2004 Nov; 48(11):4460-2. PubMed ID: 15504883
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
[TBL] [Abstract][Full Text] [Related]
20. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
